Coronary artery disease (CAD) is caused by atherosclerosis, the progressive accumulation of cholesterol-rich plaque inside the coronary arteries. Every major intervention available for CAD, from medication to angioplasty to bypass surgery, addresses the consequences of this process. Only cholesterol control addresses the process itself.
This distinction matters enormously in clinical practice. Research published in the International Lipid Expert Panel's 2024 position paper confirmed that as much as two-thirds of the atherosclerotic cardiovascular disease burden is modifiable, particularly by lipid-lowering therapy. The same paper established the three principles that now govern modern CAD cholesterol management: lower is better, for longer, and the earlier the better.
These three words summarise why cholesterol control is not simply a complement to coronary artery disease treatments. It is a treatment in its own right, with as strong an evidence base as any surgical procedure, and one that continues working long after a stent has been placed or a bypass has been performed.
At Dr. Humayun Speciality Hospital, T. Nagar, Chennai, the management of coronary artery disease integrates revascularisation, optimal medical therapy, and structured cholesterol management into a single coordinated care plan because treating one without the others produces demonstrably inferior outcomes.
The CAD-Cholesterol Connection: Why They Are Inseparable
Coronary artery disease and elevated LDL cholesterol are not parallel problems that happen to coexist in the same patient. They are the same problem viewed from different angles.
Atherosclerosis begins when LDL cholesterol particles penetrate the inner lining of the coronary arterial wall and become trapped. The immune system responds to these trapped particles as a threat, triggering an inflammatory process that over decades creates the plaque responsible for both stable angina and acute heart attacks. Every additional year of elevated LDL adds to this plaque burden. Every year of effective cholesterol control slows plaque accumulation and, over time, promotes partial plaque regression.
This is what the 2025 ESC/EAS Focused Update on Dyslipidaemia Guidelines means when it states that current evidence strongly emphasises not only that "lower is better" but also "the earlier the better" for LDL cholesterol reduction in patients with established cardiovascular disease. The plaque that has already formed is the legacy of decades of elevated cholesterol. The plaque that will form in the next decade depends on what happens to cholesterol from today.
For patients who have undergone coronary angioplasty or bypass surgery, this principle has immediate clinical relevance. Revascularisation restores blood flow through treated arteries. It does not remove plaque from untreated vessels, nor does it prevent new plaque formation in the future. Only sustained, intensive cholesterol reduction achieves that.
Understanding the Targets: Which Numbers Matter in CAD
The 2026 ACC/AHA/AHA Guideline on the Management of Dyslipidemia, the most current evidence-based framework available, and the 2024 ESC Chronic Coronary Syndrome Update align on the cholesterol targets for patients with confirmed coronary artery disease:
-
LDL-C target for established CAD: Below 55 mg/dL (1.4 mmol/L) AND a reduction of at least 50% from the patient's baseline untreated level. This dual target, an absolute number and a relative reduction, ensures that even patients who start with modestly elevated LDL receive meaningful treatment.
-
Non-HDL cholesterol: Below 85 mg/dL for very high-risk CAD patients, capturing the atherogenic contribution of triglyceride-rich lipoproteins beyond LDL. HDL cholesterol: While no medication reliably raises HDL to therapeutic benefit, low HDL (below 40 mg/dL in men, below 50 mg/dL in women) remains an independent cardiovascular risk marker that informs overall risk assessment.
-
Lipoprotein(a) (Lp(a)): An emerging risk factor increasingly recognised in guidelines. Elevated Lp(a) is genetically determined and does not respond to statins, making it an important marker for identifying patients at residual risk despite optimal standard therapy. The 2026 ACC/AHA Dyslipidemia Guideline specifically addresses Lp(a) measurement as part of cardiovascular risk assessment.
-
Triglycerides: Elevated triglycerides (above 150 mg/dL fasting) are associated with residual cardiovascular risk and are managed through dietary modification, omega-3 fatty acid therapy, and treatment of underlying causes including diabetes and metabolic syndrome.
Most CAD patients in India are significantly above the LDL-C target of 55 mg/dL at the time of diagnosis, and a substantial proportion remain above target even when treated, due to under-dosing of statins, poor adherence, or inadequate escalation to combination therapy.
Coronary Artery Disease Treatments: Medical Therapy
Medical therapy is the foundation of coronary artery disease treatment for every patient, regardless of whether revascularisation has been performed. The core medical treatment components include:
-
Antiplatelet therapy: Aspirin (75 to 100 mg daily) is the cornerstone antiplatelet agent for all CAD patients. Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as clopidogrel or ticagrelor) is required for at least 6 to 12 months after coronary stenting and for 12 months after an acute coronary syndrome.
-
Beta-blockers: Reduce heart rate and myocardial oxygen demand, relieve angina, and improve survival after myocardial infarction. Used for all post-MI patients with reduced left ventricular function and for those with ongoing angina.
-
ACE inhibitors or ARBs: Reduce the workload of the heart, prevent adverse cardiac remodelling after myocardial infarction, and provide cardiovascular protection independent of blood pressure lowering. Recommended for all CAD patients with reduced ejection fraction, hypertension, or diabetes.
-
Nitrates: Short-acting glyceryl trinitrate (GTN spray or tablets) provides rapid relief of acute angina episodes. Long-acting nitrates are used when angina is not adequately controlled with other agents.
-
Rate control and rhythm management: For patients with atrial fibrillation coexisting with CAD, anticoagulation and rate or rhythm control are coordinated with antiplatelet and cholesterol management.
The Cholesterol Treatment Ladder in CAD
The 2024-2026 guidelines establish a clear, evidence-based escalation strategy for cholesterol-lowering therapy in CAD patients. The principle is to reach the LDL-C target of below 55 mg/dL using whatever combination of agents is required, escalating stepwise:
Step 1: High-Intensity Statin Therapy
High-intensity statins (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily) are the mandatory first-line treatment for all CAD patients. They reduce LDL-C by approximately 50% from baseline and provide cardiovascular benefits beyond cholesterol lowering through anti-inflammatory and plaque-stabilising effects. The 2024 JACC Asia chronic coronary syndrome update confirms that high-intensity statins are recommended up to the maximum tolerated dose to achieve the LDL-C goal.
Step 2: Adding Ezetimibe
When high-intensity statin therapy alone does not achieve the target, ezetimibe 10 mg daily is added. Ezetimibe works differently from statins: it blocks cholesterol absorption in the intestine rather than reducing its synthesis in the liver. The combination of statin and ezetimibe reduces LDL-C by an additional 15 to 20% beyond statin monotherapy. The IMPROVE-IT trial demonstrated that statin-ezetimibe combination produces fewer cardiovascular events than statin alone at equivalent LDL-C levels.
Step 3: PCSK9 Inhibitors
For patients who remain above target on maximum tolerated statin plus ezetimibe, PCSK9 inhibitors (evolocumab or alirocumab, given as subcutaneous injections every 2 to 4 weeks) provide an additional 50 to 60% LDL-C reduction. They are particularly relevant for patients with very high cardiovascular risk including those with recent acute coronary syndrome, familial hypercholesterolaemia, or elevated Lp(a). PCSK9 inhibitors are approved in India and increasingly accessible.
Step 4: Inclisiran
Inclisiran is a newer RNA-interference therapy targeting PCSK9 production at the genetic level. It is given as a subcutaneous injection twice yearly after an initial loading dose, providing equivalent LDL-C reduction to PCSK9 inhibitors with significantly improved adherence due to the infrequent dosing schedule.
Step 5: Bempedoic Acid
The 2025 ESC/EAS Focused Update specifically endorses bempedoic acid as a treatment option for patients unable to tolerate statins. It works upstream of statins in the cholesterol synthesis pathway and reduces LDL-C by approximately 25% as monotherapy or in combination with ezetimibe.
Coronary Artery Disease Treatments: Revascularisation
When medical therapy does not adequately control angina, or when coronary anatomy poses an imminent threat to the heart muscle, revascularisation procedures restore blood flow directly.
-
Percutaneous Coronary Intervention (PCI): Angioplasty with stenting opens blocked or significantly narrowed coronary arteries through a catheter-based approach. PCI is the preferred revascularisation strategy for most single and double vessel CAD and for acute heart attacks. Modern drug-eluting stents maintain vessel patency with significantly lower restenosis rates than older bare-metal devices.
-
Coronary Artery Bypass Grafting (CABG): Surgical creation of new blood flow routes around blocked arteries using grafted blood vessels (internal mammary artery, radial artery, saphenous vein). CABG is preferred for three-vessel CAD, left main disease, and complex anatomy, particularly in patients with diabetes, where it produces superior long-term outcomes over PCI.
-
A critical point that is often underemphasised: neither PCI nor CABG removes atherosclerosis from the coronary arteries. They restore blood flow through the treated segment. Cholesterol-lowering therapy is required after both procedures to prevent new plaque formation in untreated segments and to slow disease progression throughout the coronary circulation.
New Additions to the CAD Treatment Toolkit
Two drug classes initially developed for diabetes have demonstrated significant cardiovascular benefits in CAD patients with or without diabetes, earning recommendations in the latest international guidelines.
-
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Reduce the risk of cardiovascular death and hospitalisation for heart failure in CAD patients with Type 2 diabetes. The 2024 JACC Asia chronic coronary syndrome update recommends SGLT2 inhibitors and GLP-1 receptor agonists for patients with Type 2 diabetes and CAD to reduce cardiovascular events, regardless of baseline glycated haemoglobin levels.
-
GLP-1 receptor agonists (semaglutide, liraglutide): Reduce cardiovascular events in patients with established ASCVD and Type 2 diabetes. Semaglutide is now specifically considered for overweight or obese CAD patients without Type 2 diabetes, where its weight-reducing effects produce meaningful cardiovascular risk reduction.
These agents are now part of the optimal medical therapy conversation for CAD patients across multiple risk categories, not solely for those with diabetes.
Lifestyle Treatment: What the Evidence Actually Says
Lifestyle modification is not a soft recommendation that supplements real treatment in CAD. It is a treatment with quantified cardiovascular benefits that augment and in some cases exceed what medication alone achieves.
-
Dietary changes: The 2025 ESC/EAS Focused Update on Dyslipidaemia Guidelines endorses a heart-healthy diet to lower LDL cholesterol, including reduced saturated fat, elimination of trans fats, increased soluble fibre, and plant stanols and sterols in the diet. In the Indian dietary context, this translates to limiting ghee and coconut oil to small quantities, replacing refined carbohydrates with whole grains and legumes, and increasing vegetable and fruit intake.
-
Physical activity: Regular moderate-intensity exercise lowers LDL, raises HDL, reduces blood pressure, reduces bodyweight, improves insulin sensitivity, and reduces cardiac mortality independently of its effects on lipid levels. The target of 150 minutes per week of moderate aerobic activity is a clinical recommendation in CAD management, not a wellness suggestion.
-
Smoking cessation: Smoking is independently and powerfully atherogenic. Cessation is the single most impactful lifestyle intervention available for CAD patients, reducing cardiovascular events significantly within the first year.
-
Weight management: Excess abdominal adiposity drives dyslipidaemia, hypertension, insulin resistance, and systemic inflammation, all of which contribute to atherosclerosis progression. Even a 5 to 10% weight reduction produces measurable improvements in the lipid profile.
Why Regular Cardiology Follow-Up Makes the Difference
Coronary artery disease is a lifelong condition. Its management is not completed by a stent placement, a bypass operation, or even the initiation of the right medications. It requires consistent monitoring of the cholesterol targets, assessment of treatment response, medication adjustment, and identification of any symptom change that may indicate disease progression.
For CAD patients in Chennai, the most actionable step after any intervention or treatment initiation is a structured follow-up plan with a cardiologist who:
Reviews the lipid profile at 6 to 12 weeks after any change in lipid-lowering therapy to assess LDL-C response and guide further escalation if needed.
Monitors for statin-related side effects including muscle symptoms and liver enzyme changes in the early months of treatment.
Reassesses cardiovascular risk annually, accounting for any new diagnoses, changes in blood pressure or blood sugar control, or emergence of new risk factors.
Adjusts antiplatelet therapy duration based on the balance of bleeding and ischaemic risk, particularly relevant in the post-PCI period.
Ensures that the LDL-C target of below 55 mg/dL is actually being achieved, not simply that a statin has been prescribed.
The gap between being on treatment and being on adequate treatment is where a significant proportion of India's preventable coronary events occur.
Heart Care at Dr. Humayun Speciality Hospital, T. Nagar, Chennai
At Dr. Humayun Speciality Hospital, coronary artery disease treatment is delivered as an integrated programme, not a series of disconnected interventions.
The cardiology team provides:
-
Comprehensive lipid profiling including LDL-C, non-HDL, HDL, triglycerides, and Lp(a) for all CAD patients, establishing a baseline against which treatment response is measured.
-
Statin therapy initiation and optimisation, ensuring high-intensity dosing is used unless specifically contraindicated, with early addition of ezetimibe when LDL-C targets are not achieved on statin monotherapy.
-
PCSK9 inhibitor prescription and monitoring for patients with very high cardiovascular risk who remain above LDL-C targets despite maximum tolerated statin plus ezetimibe.
-
PCI and CABG coordination, including pre-procedure lipid optimisation and post-procedure cholesterol follow-up to ensure that revascularisation is accompanied by the medical therapy that protects the long-term result.
-
Structured long-term follow-up, with lipid profile review at appropriate intervals and proactive escalation of therapy when targets are not being met.
-
Integrated diabetes and metabolic care, with the cardiology team working alongside the diabetology team for CAD patients with Type 2 diabetes, incorporating SGLT2 inhibitors and GLP-1 agonists where indicated.
Treat the Disease, Not Just the Episode
A heart attack is an episode. Coronary artery disease is the disease. The stent treats the episode. Cholesterol control treats the disease. Both are necessary. Neither alone is sufficient.
Diagnosed with coronary artery disease or concerned about your cholesterol?
Chat with our care assistant for quick guidance and support and book a cardiology consultation at Dr. Humayun Speciality Hospital, T. Nagar, Chennai.
